Amar D. Levens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amar D. Levens has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Jan. A. R. Moes
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
4 shared publications - Jesse Joachim Swen
Department of Clinical Pharmacy & Toxicology Leiden University Medical Center Leiden The Netherlands
3 shared publications - Adriaan J. van der Meer
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications - Aiko P. J. de Vries
Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands
2 shared publications - Bart van Hoek
Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands
2 shared publications - Danny van der Helm
Leiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, Leiden, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in JHEP Reports
- p. 102058
Azathioprine versus mycophenolate mofetil in treatment-naive autoimmune hepatitis: 3-year follow-up of the CAMARO-trial.
- 15 October 2026
- Published by Elsevier in JHEP Reports
- p. 102058
Open AccessAzathioprine versus mycophenolate mofetil in treatment-naive autoimmune hepatitis: 3-year follow-up of the CAMARO-trial.
- Open Access
- 22 July 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (9) , 1339-1351
Low Tacrolimus C0/Dose Ratio is Associated with Higher Cmax and AUC Despite Similar Pre-dose Concentrations
Background and Objective Tacrolimus therapeutic drug monitoring after kidney transplantation is primarily guided by the pre-dose concentration (C0), assuming it reflects overall drug exposure. At the same time, the tacrolimus concentration-to-dose ratio (C0/dose) has emerged as a marker associated with clinical outcomes after transplantation, suggesting that differences in peak (maximum concentration [Cmax]) and total tacrolimus exposure (area under the concentration–time curve from 0 to 24 h [AUC0–24h]) may not be fully captured by C0 alone. Methods In 534 kidney transplant recipients followed for up to 13 months post-transplantation, 635 tacrolimus pharmacokinetic profiles with corresponding C0 values were analyzed. The C0/dose category was defined using the C0/dose ratio and classified as fast (1·mg⁻1, n = 344), intermediate (1.05–1.53, n = 127), or slow (≥1.54, n = 164). Analyses were restricted to measurements with C0 between 5.0 and 6.0 ng/mL to compare Cmax and AUC0–24h across C0/dose categories and tacrolimus formulations (immediate release vs extended release) using linear mixed-effects models. Sensitivity analyses evaluated C0-adjusted Cmax and AUC0–24h in the full cohort (4271 pharmacokinetic profiles) and assessed consistency when Cmax was predicted using population pharmacokinetic models. Results Despite comparable C0 levels, the fast C0/dose category was associated with substantially higher tacrolimus doses and had higher peak concentration and total exposure. Under immediate-release tacrolimus, Cmax and AUC0–24h were 30 and 18% higher, respectively, compared with the slow category. Under extended-release tacrolimus, differences were more pronounced, with 86% higher Cmax (estimate: 1.86, 95% confidence interval 1.61–2.13) and 46% higher AUC0–24h (estimate: 1.45, 95% confidence interval 1.35–1.55). The intermediate category showed a smaller but consistent increase in exposure. Higher Cmax and AUC0–24h relative to C0 in fast metabolizers remained consistent in the full cohort and when Cmax was model predicted. Conclusions Tacrolimus C0 alone incompletely reflects the full pharmacokinetic profile and may miss clinically relevant peak-related toxicity. The C0/dose ratio may help identify patients with disproportionate exposure, in whom more individualized therapeutic drug monitoring beyond C0 monitoring is recommended.
- 22 July 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (9) , 1339-1351
Open AccessLow Tacrolimus C0/Dose Ratio is Associated with Higher Cmax and AUC Despite Similar Pre-dose Concentrations
Background and Objective Tacrolimus therapeutic drug monitoring after kidney transplantation is primarily guided by the pre-dose concentration (C0), assuming it reflects overall drug exposure. At the same time, the tacrolimus concentration-to-dose ratio (C0/dose) has emerged as a marker associated with clinical outcomes after transplantation, suggesting that differences in peak (maximum concentration [Cmax]) and total tacrolimus exposure (area under the concentration–time curve from 0 to 24 h [AUC0–24h]) may not be fully captured by C0 alone. Methods In 534 kidney transplant recipients followed for up to 13 months post-transplantation, 635 tacrolimus pharmacokinetic profiles with corresponding C0 values were analyzed. The C0/dose category was defined using the C0/dose ratio and classified as fast (1·mg⁻1, n = 344), intermediate (1.05–1.53, n = 127), or slow (≥1.54, n = 164). Analyses were restricted to measurements with C0 between 5.0 and 6.0 ng/mL to compare Cmax and AUC0–24h across C0/dose categories and tacrolimus formulations (immediate release vs extended release) using linear mixed-effects models. Sensitivity analyses evaluated C0-adjusted Cmax and AUC0–24h in the full cohort (4271 pharmacokinetic profiles) and assessed consistency when Cmax was predicted using population pharmacokinetic models. Results Despite comparable C0 levels, the fast C0/dose category was associated with substantially higher tacrolimus doses and had higher peak concentration and total exposure. Under immediate-release tacrolimus, Cmax and AUC0–24h were 30 and 18% higher, respectively, compared with the slow category. Under extended-release tacrolimus, differences were more pronounced, with 86% higher Cmax (estimate: 1.86, 95% confidence interval 1.61–2.13) and 46% higher AUC0–24h (estimate: 1.45, 95% confidence interval 1.35–1.55). The intermediate category showed a smaller but consistent increase in exposure. Higher Cmax and AUC0–24h relative to C0 in fast metabolizers remained consistent in the full cohort and when Cmax was model predicted. Conclusions Tacrolimus C0 alone incompletely reflects the full pharmacokinetic profile and may miss clinically relevant peak-related toxicity. The C0/dose ratio may help identify patients with disproportionate exposure, in whom more individualized therapeutic drug monitoring beyond C0 monitoring is recommended.
- Open Access
- 22 April 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (6) , 863-882
Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility
Background and Objective Venetoclax shows substantial pharmacokinetic (PK) variability and frequent toxicity, making it an archetypal candidate for PK monitoring. Capillary microsampling may facilitate decentralized PK monitoring of venetoclax. However, clinical validation is lacking. This study aimed to clinically validate capillary microsampling for venetoclax and to assess the feasibility of home-based self-microsampling. Methods Adult patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) receiving oral venetoclax therapy provided paired venous plasma and capillary samples using dried blood spot (DBS) and volumetric absorptive microsampling (VAMS) devices. We evaluated individualized hematocrit-based microsample-to-plasma correction models and previously published whole-blood-to-plasma conversion strategies. Agreement and predictive performance were assessed according to international microsampling validation criteria. The feasibility of home-based self-microsampling was evaluated by examining patients’ ability to collect samples independently, the proportion of usable returned samples, and device usability. Results A total of 25 patients contributed 64 sets of paired venous plasma, DBS, and VAMS samples. Uncorrected DBS and VAMS venetoclax concentrations underestimated plasma concentrations (mean bias − 21% and − 14%, respectively) and showed clear hematocrit dependence. Individualized hematocrit–plasma/microsample ratio models showed excellent performance, with 95% of DBS and 91% of VAMS concentrations within ± 20% of plasma and low bias and imprecision across all validation metrics. Literature-based correction strategies showed lower acceptance rates and wider limits of agreement. Among patients attempting self-microsampling, 18 of 21 sampled independently, 76% of returned DBS/VAMS samples were suitable for analysis, and usability ratings were higher for VAMS than DBS. Conclusions Capillary microsampling enables accurate venetoclax quantification in patients with AML and CLL when individualized hematocrit-based microsample-to-plasma conversion is applied. Both DBS and VAMS met international validation criteria, and home-based self-microsampling proved feasible. Venetoclax home-based self-microsampling warrants further study as a tool for decentralized PK monitoring.
- 22 April 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (6) , 863-882
Open AccessClinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility
Background and Objective Venetoclax shows substantial pharmacokinetic (PK) variability and frequent toxicity, making it an archetypal candidate for PK monitoring. Capillary microsampling may facilitate decentralized PK monitoring of venetoclax. However, clinical validation is lacking. This study aimed to clinically validate capillary microsampling for venetoclax and to assess the feasibility of home-based self-microsampling. Methods Adult patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) receiving oral venetoclax therapy provided paired venous plasma and capillary samples using dried blood spot (DBS) and volumetric absorptive microsampling (VAMS) devices. We evaluated individualized hematocrit-based microsample-to-plasma correction models and previously published whole-blood-to-plasma conversion strategies. Agreement and predictive performance were assessed according to international microsampling validation criteria. The feasibility of home-based self-microsampling was evaluated by examining patients’ ability to collect samples independently, the proportion of usable returned samples, and device usability. Results A total of 25 patients contributed 64 sets of paired venous plasma, DBS, and VAMS samples. Uncorrected DBS and VAMS venetoclax concentrations underestimated plasma concentrations (mean bias − 21% and − 14%, respectively) and showed clear hematocrit dependence. Individualized hematocrit–plasma/microsample ratio models showed excellent performance, with 95% of DBS and 91% of VAMS concentrations within ± 20% of plasma and low bias and imprecision across all validation metrics. Literature-based correction strategies showed lower acceptance rates and wider limits of agreement. Among patients attempting self-microsampling, 18 of 21 sampled independently, 76% of returned DBS/VAMS samples were suitable for analysis, and usability ratings were higher for VAMS than DBS. Conclusions Capillary microsampling enables accurate venetoclax quantification in patients with AML and CLL when individualized hematocrit-based microsample-to-plasma conversion is applied. Both DBS and VAMS met international validation criteria, and home-based self-microsampling proved feasible. Venetoclax home-based self-microsampling warrants further study as a tool for decentralized PK monitoring.
- Open Access
- 22 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 942-952
Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5 *6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%). We conducted a retrospective, longitudinal cohort study using real‐world data from 1,461 adult kidney transplant recipients across 67 countries, analyzing 4,293 dose‐normalized 24‐hour area‐under‐the‐curve (AUC 0‐24 ) measurements of tacrolimus. Patients with CYP3A5* 1/*1 were excluded. Linear mixed‐effects models (LME) were used to assess the association between CYP3A5* 6 carriage and tacrolimus exposure, adjusting for clinical factors and ancestry using both HLA‐based principal components and country of birth. CYP3A5 *6 carriers had a 17% lower dose‐normalized AUC 0‐24 than CYP3A5 *3 carriers ( P = 0.015). Sensitivity analyses using dose‐normalized trough concentrations (C 0 ) confirmed these findings, with a 20% lower exposure in CYP3A5 *6 carriers ( P = 0.011). An interval‐based analysis demonstrated persistently lower tacrolimus exposure across the first post‐transplant year. All CYP3A5 *6‐containing genotypes showed significantly lower dose‐normalized AUC 0‐24 compared to CYP3A5 *3/*3, the most common genotype in European populations, with the largest reductions observed in CYP3A5 *1/*6 (−39%; P < 0.001) and CYP3A5 *3/*6 (−18%; P = 0.006). African origin, defined by country of birth, was independently associated with a 23% higher AUC 0‐24 ( P < 0.001). This is the first study to demonstrate a differential effect on tacrolimus exposure between the CYP3A5 *6 and CYP3A5 *3 loss‐of‐function alleles. Our results may help bridge the ethnicity gap, advance the applicability of pharmacogenomic findings, and promote health equity.
- 22 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 942-952
Open AccessLower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5 *6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%). We conducted a retrospective, longitudinal cohort study using real‐world data from 1,461 adult kidney transplant recipients across 67 countries, analyzing 4,293 dose‐normalized 24‐hour area‐under‐the‐curve (AUC 0‐24 ) measurements of tacrolimus. Patients with CYP3A5* 1/*1 were excluded. Linear mixed‐effects models (LME) were used to assess the association between CYP3A5* 6 carriage and tacrolimus exposure, adjusting for clinical factors and ancestry using both HLA‐based principal components and country of birth. CYP3A5 *6 carriers had a 17% lower dose‐normalized AUC 0‐24 than CYP3A5 *3 carriers ( P = 0.015). Sensitivity analyses using dose‐normalized trough concentrations (C 0 ) confirmed these findings, with a 20% lower exposure in CYP3A5 *6 carriers ( P = 0.011). An interval‐based analysis demonstrated persistently lower tacrolimus exposure across the first post‐transplant year. All CYP3A5 *6‐containing genotypes showed significantly lower dose‐normalized AUC 0‐24 compared to CYP3A5 *3/*3, the most common genotype in European populations, with the largest reductions observed in CYP3A5 *1/*6 (−39%; P < 0.001) and CYP3A5 *3/*6 (−18%; P = 0.006). African origin, defined by country of birth, was independently associated with a 23% higher AUC 0‐24 ( P < 0.001). This is the first study to demonstrate a differential effect on tacrolimus exposure between the CYP3A5 *6 and CYP3A5 *3 loss‐of‐function alleles. Our results may help bridge the ethnicity gap, advance the applicability of pharmacogenomic findings, and promote health equity.
- Open Access
- 13 December 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (4) , 576-585
An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis
- 13 December 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (4) , 576-585
Open AccessAn open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis
- Open Access
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors
Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y12-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—particularly in an outpatient setting—remains limited. We conducted a proof-of-concept study to evaluate the feasibility of CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel through point-of-care (POC) PGx testing in the community pharmacy. Multiple feasibility outcomes were assessed. Overall, 144 patients underwent CYP2C19 PGx testing in 27 community pharmacies. Successful test results were obtained in 142 patients (98.6%). De-escalation to clopidogrel occurred in 19 patients (20%) out of 95 (67%) eligible for therapy de-escalation, which was mainly due to PGx testing not being included in cardiology guidelines. Out of the 119 patients (84%) and 14 pharmacists (100%) surveyed, 109 patients (92%) found the community pharmacy a suitable location for PGx testing, and the majority of pharmacists (86%) thought it has added value. Net costs due to PGx testing were estimated at €43 per patient, which could be reduced by earlier testing and could turn into savings if de-escalation would double to 40%. Although the observed de-escalation rate was low, POC CYP2C19-guided de-escalation to clopidogrel appears feasible in a community pharmacy setting.
Open AccessFeasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors
Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y12-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—particularly in an outpatient setting—remains limited. We conducted a proof-of-concept study to evaluate the feasibility of CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel through point-of-care (POC) PGx testing in the community pharmacy. Multiple feasibility outcomes were assessed. Overall, 144 patients underwent CYP2C19 PGx testing in 27 community pharmacies. Successful test results were obtained in 142 patients (98.6%). De-escalation to clopidogrel occurred in 19 patients (20%) out of 95 (67%) eligible for therapy de-escalation, which was mainly due to PGx testing not being included in cardiology guidelines. Out of the 119 patients (84%) and 14 pharmacists (100%) surveyed, 109 patients (92%) found the community pharmacy a suitable location for PGx testing, and the majority of pharmacists (86%) thought it has added value. Net costs due to PGx testing were estimated at €43 per patient, which could be reduced by earlier testing and could turn into savings if de-escalation would double to 40%. Although the observed de-escalation rate was low, POC CYP2C19-guided de-escalation to clopidogrel appears feasible in a community pharmacy setting.
- 1 April 2016
- Published by Elsevier in Psychiatry Research
- Vol. 238, 189-195
Reliability and validity of an instrument for the assessment of bradykinesia
- 1 April 2016
- Published by Elsevier in Psychiatry Research
- Vol. 238, 189-195
Reliability and validity of an instrument for the assessment of bradykinesia